Point72 Asia (Singapore) Pte. Ltd. Akero Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 2,848 shares of AKRO stock, worth $121,666. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,848
Previous 9,230
69.14%
Holding current value
$121,666
Previous $265 Million
70.08%
% of portfolio
0.02%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
209Shares Held
66.9MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$293 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$258 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$239 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$224 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$185 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.98B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...